Abstract
Thromboembolism is frequent in infective endocarditis (IE). However, the optimal antithrombotic regimen in IE is unknown. Staphylococcus aureus (SA) is the leading cause of IE. First studies emphasize increased platelet reactivity by SA. In this pilot study, we hypothesized that platelet reactivity is increased in patients with SA− IE, which could be abrogated by antiplatelet medication. We conducted a prospective, observatory, single-center cohort study in 114 patients with IE, with four cohorts: (1) SA coagulase positive IE without aspirin (ASA) medication, (2) coagulase negative IE without ASA, (3) SA coagulase positive IE with ASA, (4) coagulase negative IE with ASA. Platelet function was measured by Multiplate electrode aggregometry, blood clotting by ROTEM thromboelastometry. Bleeding events were assessed according to TIMI classification. In ASA-naïve patients, aggregation with ADP was increased with coag. pos. IE (coagulase negative: 39.47 ± 4.13 AUC vs. coagulase positive: 59.46 ± 8.19 AUC, p = 0.0219). This was abrogated with ASA medication (coagulase negative: 42.4 ± 4.67 AUC vs. coagulase positive: 45.11 ± 6.063 AUC p = 0.7824). Aspirin did not increase bleeding in SA positive patients. However, in SA negative patients with aspirin, red blood cell transfusions were enhanced. SA coagulase positive IE is associated with increased platelet reactivity. This could be abrogated by aspirin without increased bleeding risk. The results of this pilot study suggest that ASA might be beneficial in SA coagulase positive IE. This needs to be confirmed in clinical trials.
Similar content being viewed by others
Introduction
Infective endocarditis (IE) is a severe disease, causing destruction of endocardial structures and resulting in high morbidity and mortality1,2. Despite all improvements in medical care and therapy, the overall mortality remains high (up to 18%) due to cardiac failure and thromboembolic complications2. In vitro studies suggested that increased platelet activation plays a central role in the pathophysiology of IE3. These studies showed that IE inducing bacteria can interact with platelets and coagulation factors4,5. This facilitates microbial surface binding and formation of vegetations promoting thromboembolic events6. Especially Staphylococcus aureus (SA) and its virulence factor clumping factor A (ClfA) have been shown to trigger platelet adhesion and to directly induce platelet aggregation in vitro7,8. Therefore, IE inducing bacteria can be divided in SA coagulase positive and coagulase negative bacteria depending on their ability to induce clotting reactions. ClfA allows SA to cover its surface with proteins and platelets from the host organism and to escape immune response9. As underlying mechanisms for the pro-thrombotic effects, fibrinogen and IgG dependent pathways were suggested8,10,11. Furthermore, SA also influences the coagulation system: it secretes soluble virulence factors, like staphylocoagulase (Coa) and von Willebrand factor-binding protein (vWbp) that directly interact with prothrombin, leading to the conversion of fibrinogen to fibrin10,12,13.
However, investigation on platelet function in IE-patients is rare. Therefore, we compared platelet function of patients with SA coagulase positive (SA+) and coagulase negative (SA−) IE. Furthermore, we investigate the effects of acetylsalicylic acid (ASA) as antiplatelet medication in these patients.
Methods
Study design, patient population
In this observatory, single-center cohort study, we analysed 114 patients with clinically proven IE with indication for valve surgery in the University Hospital Düsseldorf, Germany from 2013 to 2017. Informed consent was obtained from all patients. Germs were detected in blood cultures or by microbiological examination of the explanted valve respectively. Four study groups were defined depending on prior and perioperatively continued ASA medication (oral administration of 100 mg ASA once per day) and SA status (Fig. 1). Age under 18, coagulation disorders, haematological diseases and platelet medication others than ASA were exclusion criteria. After surgery, patients were on oral anticoagulation for 3 months, followed by indefinite single antiplatelet medication. The study conformed to the declaration of Helsinki and was approved by the Ethics Committee of the University of Düsseldorf (2018-105-RetroDEuA).
Platelet function and coagulation parameters testing
Blood samples were collected in citrate vacutainers (1:10) immediately before valve surgery. Platelet function was measured as point of care test by multiple electrode aggregometry (MEA, Multiplate, Roche diagnostics, Germany) with adenosine diphosphate (ADP) and thrombin receptor activating peptide (TRAP) as stimulants (Roche, Germany). Aggregation was measured as area under the Curve (AUC). In addition, thromboelastometry (ROTEM sigma, Werfen, Germany) was used to evaluate specific plasmatic coagulation parameters like FIBTEM A10, EXTEMCT and INTEM CT. As standard coagulation parameters, Quick, international normalized ratio (INR), and partial thromboplastin time (PTT) were determined.
Amount of erythrocyte transfusions
To estimate the risk of perioperative bleeding the amount of erythrocyte transfusions was evaluated for each patient. The documented number of administered erythrocyte concentrates was counted from operating theatre and intensive care unit transfusion protocols.
Standardized bleeding assessment with thrombolysis in myocardial infarction (TIMI) bleeding criteria
Bleeding was standardized with TIMI bleeding criteria. As criteria fatal bleeding, perioperative intercranial bleeding, reoperation after closure of sternotomy to control bleeding, transfusion of more than 5 packed red blood cells within 48 h and chest tube output more than 2 L within 24 h were evaluated.
One-year follow-up of clinical endpoints
Follow-up was conducted for clinical endpoints at 1 year after surgery. Major adverse cardiovascular and cerebrovascular events (MACCE) were assessed including stroke, death, myocardial infarction and bleeding events.
Statistics
All statistics and analyses were conducted in IBM SPSS-Software (New York, USA) and GraphPad-Prism software (GraphPad software Inc, San Diego). Kolmogorov–Smirnov-Test and Shapiro–Wilks-Test were used to prove normal distributions. Results and descriptive statistics are presented as mean with standard deviations (mean ± SD) for continuous variables. Binary variables are presented as absolute numbers with percentage amount of the population in brackets (No. [%]). Unpaired t tests, One-way ANOVA and Kruskal–Wallis tests were used for comparison of continuous variables, while chi square or the Fisher’s exact test were used to analyse categorical variables. Multivariable linear regression was used to show effects of independent variables on a dependent variable. Kaplan–Meier curves with log-rank tests for trend were used to analyse results from follow-up of clinical events. P-values below 0.05 were considered significant.
Ethics committee approval
The study conformed to the Declaration of Helsinki and was approved by the University of Düsseldorf Ethics Committee (No.: 2018–105-RetroDEuA).
Results
Study patients and baseline characteristics
In this study we included 114 patients with proven IE. This cohort was divided in four groups: (1) 38 patients with Coagulase negative (SA−) IE naïve to ASA, (2) 14 patients with SA+ IE naïve to ASA, (3) 53 patients with SA− IE and ASA medication and (4) 9 patients with SA+ IE and ASA medication (Fig. 1).
In patients naïve to ASA medication, overall mean age was 59.3 ± 15.3 years. 38 patients had a SA− and 14 patients a SA+ IE. Patients with SA+ IE were slightly younger (SA−: 64.1 ± 12.4 years vs. SA+: 54.5 ± 18.4 years, p = 0.034) and mostly female (SA−: 29 [76.3%] vs. SA+: 6 [42.9%], p = 0.043). Regarding other baseline parameters, comorbidities, comedication and laboratory parameters, there were no further differences between groups.
Overall mean age in the group with ASA medication was 63.16 ± 13.72 years. Within this group, 53 patients had a SA− and 9 patients had a SA+ IE. There were no significant differences between baseline parameters, comorbidities and comedication (Supplementary Tables 1, 2 and 3).
Platelet function testing by Multiplate
In patients without ASA medication, mean ADP induced platelet aggregation measured by MEA, was significantly higher in those patients with SA+ IE (SA−: 39.47 ± 4.13 AUC vs. SA+: 59.46 ± 8.19 AUC, p = 0.0219). This finding was robust after adjustment for age, gender, C-reactive protein (CRP) and platelet count in a multivariate linear regression model (SA+—Standardized coefficient: 30.72, 95% CI: 14.5–46.9, p = < 0.0001; Age—Standardized coefficient: 0.48, 95% CI: 0.01–0.95, p = 0.044; Gender—Standardized coefficient: 4.79, 95% CI: − 9.67 to 19.24, p = 0.508; CRP—Standardized coefficient: 0.06, 95% CI: − 0.46 to 0.57, p = 0.824; platelet count: 0.17, 95% CI: 0.94–0.24, p = < 0.0001). Platelet reactivity did not differ for TRAP induced aggregation (TRAP—SA−: 85.08 ± 5.075 AUC vs. SA+: 91.46 ± 9.715 AUC, p = 0.5368) (Fig. 2, Table 1A, Supplementary Fig. 3).
In comparison, platelet aggregation did not differ between SA+ and SA− IE patients with ASA medication (ADP—SA−: 42.4 ± 4.67 AUC vs. SA+: 45.11 ± 6.063 AUC p = 0.7824; TRAP—SA−: 84.78 ± 5.407 AUC vs. SA+: 77.11 ± 7.725 AUC p = 0.5608). This finding remained insignificant in multivariate analysis (SA−—Standardized coefficient: − 4.76, 95% CI: − 20.92 to 11.40, p = 0.557; Age—Standardized coefficient: − 0.35, 95% CI: − 0.80 to 0.11, p = 0.129; Gender—Standardized coefficient: − 3.59, 95% CI: − 15.25 to 8.07, p = 0.539; CRP—Standardized coefficient: 0.84, 95% CI: − 0.08 to 1.75, p = 0.072; platelet count: 0.11, 95% CI: 0.06–0.17, p = < 0.0001) (Fig. 2, Table 1B).
Platelet function testing by ROTEM
In all four groups there were no significant differences in blood clotting measured by thromboelastometry (FIBTEM A10—SA−/ASA−: 27.94 ± 1.63 mm vs. SA+/ASA−: 32.85 ± 2.648 mm AUC vs. SA−/ASA+: 28.29 ± 1.45 mm vs. SA+/ASA+: 28.78 ± 3.25 mm AUC, p = 0.4637; EXTEM CT—SA−/ASA−: 55.56 ± 1.945 s vs. SA+/ASA−: 61.62 ± 5.144 s vs. SA−/ASA+: 55.96 ± 1.471 s vs. SA+/ASA+: 57.78 ± 4.904 s, p = 0.4590; INTEM CT—SA−/ASA−: 141.6 ± 6.022 s vs. SA+/ASA−: 160.2 ± 7.597 s vs. SA−/ASA+: 147.8 ± 3.258 s vs. SA+/ASA+: 154.9 ± 2.318 s, p = 0.1833) (Fig. 3).
Coagulation parameters
Further plasmatic coagulation parameters measured by Quick, INR, PTT and thrombin time did not differ between groups (Quick—SA−/ASA−: 74.03 ± 3.021% vs. SA+/ASA−: 71.77 ± 4.684% vs. SA−/ASA+: 74.27 ± 2.687% vs. SA+/ASA+: 66.44 ± 6.539%, p = 0.6777; INR—SA−/ASA−: 1.414 ± 0.2344 vs. SA+/ASA−: 1.16 ± 0.04 vs. SA−/ASA+: 1.167 ± 0.035 vs. SA+/ASA+: 1.25 ± 0.15, p = 0.4624; PTT—SA−/ASA−: 26.83 ± 0.7802 s vs. SA+/ASA−: 29.77 ± 2.964 s vs. SA−/ASA+: 27.51 ± 0.756 s vs. SA+/ASA+: 28.56 ± 2.31 s, p = 0.4934) (Fig. 3).
Erythrocyte transfusions
The amount of erythrocyte transfusion did not differ between SA+ or SA− patients without ASA and SA+ patients with ASA. However, SA− patients with ASA required higher amounts of erythrocyte transfusions compared to the other groups (Erythrocyte transfusions—SA−/ASA−: 5.364 ± 5.719 transfusions; SA+/ASA−: 5.231 ± 4.285 transfusions; SA−/ASA+: 8.686 ± 9.195 transfusions; SA+/ASA+: 5.143 ± 3.078 transfusions) (Fig. 4).
Standardized bleeding assessment with TIMI bleeding criteria
Bleeding assessment with TIMI bleeding criteria showed no significant differences between patients without ASA medication in comparison to those patients with ASA medication and SA+ or SA− IE (Supplementary Table 4).
One-year follow-up
Patients with ASA treatment during IE before surgery had reduced mortality (Death—SA−/ASA−: 14.9% vs. SA+/ASA−: 13.3% vs. SA−/ASA+: 4% vs. SA+/ASA+: 0%; Log-rank test for trend p = 0.043). Other clinical endpoints (stroke, myocardial infarction and composite MACCE) did not differ between groups (Supplementary Fig. 1).
Discussion
The major findings of this study were that (A) ADP stimulated platelet aggregation is higher in SA+ compared to SA− IE patient. This was independently from age, gender and CRP. (B) This was abolished in patients with ASA medication. (C) ASA did not lead to an increased rate of bleeding and need for blood transfusion.
SA has different virulence factors, which interact with coagulation factors and mediate platelet activation8,10. In human platelets, ClfA is considered as a main factor for activation of human platelets by SA14. ClfA is a staphylococcal surface protein that binds the C-terminus of human fibrinogens γ-chain7,15. The adherent bivalent fibrinogen molecule can bind to the platelets GPIIb/IIIa receptor and induce crosslinking7,8. As this crosslinking alone is insufficient to trigger platelet aggregation, a second stimulating agent is required7. Rapid platelet activation has been described for simultaneous binding of ClfA specific antibodies, linking ClfA to the platelets FcγRIIa-receptor, enhancing GPIIb/IIIa receptor signalling7,16. However, other mechanisms involving ClfA are conceivable.
ADP is a main physiological agent to induce platelet aggregation through the P2Y12- and P2Y1-receptors, located on human platelets17. The P2Y12-receptor is known to activate GPIIb/IIIa receptors through a phosphoinositide-3-kinase (PI3-K) pathway17. While ClfA bound fibrinogen is presented to the GPIIb/IIIa receptor, its activation through ADP could have synergistic effects. This mechanism could lead to amplified platelet reactivity. Additionally, we conducted in-vitro experiments which showed that ADP mediated platelet aggregation can be amplified in presence of ClfA in healthy individuals (Supplementary Fig. 2).
Besides ADP, thrombin is a strong mediator of platelet aggregation. Thrombin mainly activates human platelets through the PAR-1 receptor18. SA and other bacteria can induce endogenous thrombin formation through systemic inflammatory reactions19,20. This increase of endogenous thrombin can lead to a decrease of PAR-1 expression on platelets already at very low persistent concentrations21. The decrease of PAR-1 is described as time and dose dependent and could be shown in patients with systemic inflammation21. Ex-vivo, PAR1 down-regulation comes with a decreased responsiveness to TRAP in MEA21. These two mechanisms could explain our findings that platelets of patients with coagulase positive IE had an increased responsiveness to ADP dependent platelet aggregation while TRAP dependent platelet aggregation did not differ in our study.
Beside of pathologically increased platelet activation by SA, other mechanisms should be considered. There is evidence that bloodstream infections with SA can lead to a massive inflammatory response22. In this context CRP, as common inflammatory marker, is increased. Studies showed that elevated CRP levels can affect platelet function23,24. Other factors that might influence human platelet aggregation and must be considered as confounding parameters are age and gender25. In our study, we identified that patients with SA+ IE were slightly younger and less often male compared to SA− patients. No other differences were detected between the study groups. But even after adjustments for age, gender and CRP our findings remained robust in multivariate analysis.
We also investigated thromboelastometry and coagulation parameters in patients with SA+ IE compared to patients with SA− IE. No significant differences could be shown, although previous studies suggest that SA impairs plasma clotting times and increases PTT by secreting extracellular soluble virulence factors Staphopain A and Staphopain B26.
Clinical studies have shown that patients with IE caused by SA show higher morbidity and mortality2,27. This primarily results from association of SA caused IE with higher rates of thromboembolic events leading to major neurological events and poor outcomes28,29. In this study we found that ASA treatment prior to surgery was associated with reduced 1 year mortality. However, this must be interpreted with caution. All patients had oral anticoagulation for 3 months after surgery. Additionally, the study size was not powered for multivariate analysis regarding clinical endpoints. Therefore, this has to be tested in randomized trials. However, it is well known that thromboembolic events have impact on prognosis of patients with SA+ IE, therefore antithrombotic medication might play a significant role to improve outcome29.
Previous research on IE could show that continuous ASA medication reduces the number of thromboembolic events and reduces vegetation size, confirming the importance of platelet reactivity30,31,32,33. However, data on this topic was controversial because some studies identified higher bleeding rates in IE patients on ASA therapy34,35. However, data did not show that ASA prevented thromboembolic events, which goes in line with our findings. Hence, the European Guidelines for treatment of IE do not yet recommend antiplatelet medication36. These studies did not investigate SA+ versus SA− IE patients. However, based on our results, patients with SA+ IE could particularly benefit of ASA medication. This is even underlined by the fact that ASA medication seemed to be safe in our study in SA+ patients. However, SA− patients with ASA had enhanced perioperative bleeding according to RBC transfusions. Postoperative bleeding, leading to reoperation also occurred more often in these patients. Although these findings were barely significant and case number was limited, it might underline the procoagulant effects of SA on the one hand and on the other hand emphasizes the safety of ASA medication in these patients.
Study limitations
Our study has several limitations. First it was an observatory, single-center cohort study so external validity might be limited. There is a selection bias because only patients prior to surgical treatment were included, which might have led to a lower amount of SA+ patients. Indication for surgical treatment were not recorded. This could have influenced the results as valvular dysfunctions can impact platelet function tests. Furthermore, this study used point of care tests for evaluation of coagulation and platelet function that were available in our clinical setting. Therefore, we decided to carry out platelet function tests from citrated blood to meet the standards of our local laboratory, although hirudinized blood might be the standard for multiple electrode aggregometry. This might have influenced our findings. Also, it might have been interesting to further evaluate P-selectin levels and GPIIbIIIa activation which might have been more precise to evaluate platelet activation. However, these methods were not available in our daily clinical routine. Additionally, most of the patients did not reach the reference range of ADP induced platelet function test. Therefore, it is difficult to say if SA does increase platelet aggregation in general. However, we found that SA+ patients had higher platelet aggregation as compared to control. The trial was not randomized or controlled. Therefore, other potential confounders that were not included in the multivariable analysis might have biased the results.
Conclusion
This study showed that platelet aggregation is higher in ASA medication naïve patients with SA+ IE compared to patients with SA− E. This finding was abolished in patients with ASA medication, whereas bleeding was not enhanced in these patients. This leads to the hypothesis that ASA might be beneficial in SA+ endocarditis. Randomized clinical trials are needed to test this hypothesis.
Data availability
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
Abbreviations
- ADP:
-
Adenosine diphosphate
- ASA:
-
Acetylsalicylic acid
- AUC:
-
Area under the curve
- ClfA:
-
Clumping factor A
- CRP:
-
C-reactive protein
- IE:
-
Infective endocarditis
- INR:
-
International normalized ratio
- LTA:
-
Light transmission aggregometry
- MACCE:
-
Major adverse cardiovascular and cerebrovascular events
- MEA:
-
Multiple electrode aggregometry
- PRP:
-
Platelet rich plasma
- PTT:
-
Partial thromboplastin time
- ROTEM:
-
Rotational thromboelastometry
- SA:
-
Staphylococcus aureus
- SA+:
-
Staphylococcus aureus Coagulase positive
- SA−:
-
Staphylococcus aureus Coagulase negative
- TIMI:
-
Thrombolysis in myocardial infarction
- TRAP:
-
Thrombin receptor activating peptide
References
Osler, W. The Gulstonian lectures, on malignant endocarditis. Br. Med. J. 1(1264), 577–579 (1885).
Murdoch, D. R. et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: The International Collaboration on Endocarditis-Prospective Cohort Study. Arch. Intern. Med. 169(5), 463–473 (2009).
Jung, C. J. et al. Endocarditis pathogen promotes vegetation formation by inducing intravascular neutrophil extracellular traps through activated platelets. Circulation 131(6), 571–581 (2015).
Herzberg, M. C., Brintzenhofe, K. L. & Clawson, C. C. Aggregation of human platelets and adhesion of Streptococcus sanguis. Infect. Immun. 39(3), 1457–1469 (1983).
Herzberg, M. C. et al. Phenotypic characterization of Streptococcus sanguis virulence factors associated with bacterial endocarditis. Infect. Immun. 58(2), 515–522 (1990).
Durack, D. T. Experimental bacterial endocarditis. IV. Structure and evolution of very early lesions. J. Pathol. 115(2), 81–89 (1975).
Loughman, A. et al. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol. Microbiol. 57(3), 804–818 (2005).
Bayer, A. S. et al. Staphylococcus aureus induces platelet aggregation via a fibrinogen-dependent mechanism which is independent of principal platelet glycoprotein IIb/IIIa fibrinogen-binding domains. Infect. Immun. 63(9), 3634–3641 (1995).
Guggenberger, C., Wolz, C., Morrissey, J. A. & Heesemann, J. Two distinct coagulase-dependent barriers protect Staphylococcus aureus from neutrophils in a three dimensional in vitro infection model. PLoS Pathog. 8(1), e1002434 (2012).
Vanassche, T. et al. Fibrin formation by staphylothrombin facilitates Staphylococcus aureus-induced platelet aggregation. Thromb. Haemost. 107(6), 1107–1121 (2012).
Niemann, S. et al. Soluble fibrin is the main mediator of Staphylococcus aureus adhesion to platelets. Circulation 110(2), 193–200 (2004).
Kroh, H. K., Panizzi, P. & Bock, P. E. Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. Proc. Natl. Acad. Sci. U.S.A. 106(19), 7786–7791 (2009).
Friedrich, R. et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425(6957), 535–539 (2003).
O’Brien, L. et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: Roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol. Microbiol. 44(4), 1033–1044 (2002).
Liu, C. Z., Shih, M. H. & Tsai, P. J. ClfA(221–550), a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function. Thromb. Haemost. 94(2), 286–294 (2005).
Liesenborghs, L., Verhamme, P. & Vanassche, T. Staphylococcus aureus, master manipulator of the human hemostatic system. J. Thromb. Haemost. 16(3), 441–454 (2018).
Hechler, B. & Gachet, C. P2 receptors and platelet function. Purinergic Signal 7(3), 293–303 (2011).
Jiang, L. et al. A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation. J. Thromb. Haemost. 11(5), 930–940 (2013).
Franks, Z. et al. Methicillin-resistant Staphylococcus aureus-induced thrombo-inflammatory response is reduced with timely antibiotic administration. Thromb. Haemost. 109(4), 684–695 (2013).
Mammen, E. F. The haematological manifestations of sepsis. J. Antimicrob. Chemother. 41(Suppl A), 17–24 (1998).
Reiter, R. et al. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb. Haemost. 90(5), 898–903 (2003).
Wu, D., Zhou, S., Hu, S. & Liu, B. Inflammatory responses and histopathological changes in a mouse model of Staphylococcus aureus-induced bloodstream infections. J. Infect. Dev. Ctries. 11(4), 294–305 (2017).
Fiedel, B. A. & Gewurz, H. Effects of C-reactive protein on platelet function. II. Inhibition by CRP of platelet reactivities stimulated by poly-l-lysine, ADP, epinephrine, and collagen. J. Immunol. 117(4), 1073–1078 (1976).
Skoglund, C. et al. C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. Immunol. Cell Biol. 86(5), 466–474 (2008).
Johnson, M., Ramey, E. & Ramwell, P. W. Sex and age differences in human platelet aggregation. Nature 253(5490), 355–357 (1975).
Ohbayashi, T. et al. Degradation of fibrinogen and collagen by staphopains, cysteine proteases released from Staphylococcus aureus. Microbiology 157(Pt 3), 786–792 (2011).
Lauridsen, T. K. et al. Echocardiographic findings predict in-hospital and 1-year mortality in left-sided native valve Staphylococcus aureus endocarditis: Analysis from the international collaboration on endocarditis-prospective echo cohort study. Circ. Cardiovasc. Imaging. 8(7), e003397 (2015).
Nadji, G. et al. Comparison of clinical and morphological characteristics of Staphylococcus aureus endocarditis with endocarditis caused by other pathogens. Heart 91(7), 932–937 (2005).
Han, S. M. et al. Influence of Staphylococcus aureus on outcomes after valvular surgery for infective endocarditis. J. Cardiothorac. Surg. 12(1), 57 (2017).
Anavekar, N. S. et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin. Infect. Dis. 44(9), 1180–1186 (2007).
Vanassche, T., Peetermans, W. E., Herregods, M. C., Herijgers, P. & Verhamme, P. Anti-thrombotic therapy in infective endocarditis. Expert Rev. Cardiovasc. Ther. 9(9), 1203–1219 (2011).
Nicolau, D. P., Marangos, M. N., Nightingale, C. H. & Quintiliani, R. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 39(8), 1748–1751 (1995).
Habib, A. et al. Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. Europace 15(2), 227–235 (2013).
Chan, K. L. et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J. Am. Coll. Cardiol. 42(5), 775–780 (2003).
Chan, K. L. et al. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin. Infect. Dis. 46(1), 37–41 (2008).
Habib, G. et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur. Heart J. 36(44), 3075–3128 (2015).
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University (No. 29-2019, to L.D., No. 18-2019 to A.P.) and by the German Research Foundation (LE 940/7-1 to B.L. and PO 2247/2-1 to A.P. and SFB1116 to A.P. and B.L.).
Author information
Authors and Affiliations
Contributions
A.P., L.D., R.M. and P.M. designed the study, analyzed and interpreted data and wrote the manuscript. D.N., S.Z. and C.H. collected data and revised the manuscript. T.P., B.L., Th.H., M.B., T.Z., S.S., R.H, P.A., A.L., M.K. and Ti.H. supervised the study and revised the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Polzin, A., Dannenberg, L., M’Pembele, R. et al. Staphylococcus aureus increases platelet reactivity in patients with infective endocarditis. Sci Rep 12, 12933 (2022). https://doi.org/10.1038/s41598-022-16681-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-022-16681-7
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.